Fig. 1 · Structure

Documents & Downloads

Pinometostat (EPZ-5676)

Cat. No. A12735 CAS 1380288-87-8

DOT1L Inhibitor

EPZ-5676 is a small molecule inhibitor of histone methyltransferase with potential antineoplastic activity.

In Stock

Publications for Pinometostat

2 publications citing this product

  1. Yoo H, .et al. , Cell Death Dis, 2020, Jan; 11(1): 14 PMID: 31908356
  2. Guang Bai, .et al. , Epigenetics of Chronic Pain, 2019, Pages 1-48

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

EPZ-5676 inhibits DOT1L, the histone H3 lysine-79 methyltransferase. The original biochemical study reported a DOT1L Ki of 0.08 ± 0.03 nM (mean ± SD, n = 3) and >37,000-fold selectivity within its tested methyltransferase panel. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
DOT1L (Cell-free assay) Ki 80 pM

Pinometostat (EPZ-5676) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Pinometostat (EPZ-5676) from 3 published references. In vitro models include human DOT1L and 15 additional human lysine/arginine methyltransferases.

Pinometostat (EPZ-5676) In Vitro Studies

In primary mouse dermal lymphatic endothelial cells, EPZ5676 (2 µM, 7 days) reduced H3K79me2 chromatin enrichment relative to DMSO. The methods identify Adooq A12735 for this experiment. The chromatin result does not establish drug-induced lymphatic defects in animals. [2]

DOT1L enzyme inhibition and methyltransferase selectivity

Biochemical assay · Human DOT1L and 15 additional human lysine/arginine methyltransferases [1]

EPZ-5676 inhibited DOT1L and showed strong selectivity within the tested panel. Ki is an enzyme endpoint, distinct from a cellular treatment concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DOT1L enzyme inhibitionKi 0.08 ± 0.03 nM[1]
Selectivity within the tested methyltransferase panelFold selectivity >37,000-fold[1]

Literature-Reported Treatment Conditions

Method
Enzyme inhibition; Ki fitted using the Morrison quadratic equation
Reported limits
Full assay recipe is referred to earlier work. Assay concentration range, incubation duration and enzyme-assay solvent fraction were not established from selected retrieved sections.
Methods and source locations

Compound reported in the paper: EPZ-5676 (pinometostat); Compound label in the paper: EPZ-5676

Published biochemical activity; no Adooq lot equivalence.

Biochemical enzyme inhibition methods; Results first subsection; Figure 1C,D and caption

DOT1L enzyme inhibition: Figure 1D reports mean ± SD, n = 3; Morrison quadratic fit. Results prose separately states Ki ≤0.08 nM. — Biochemical enzyme inhibition methods; Results first subsection; Figure 1C,D and caption

Selectivity within the tested methyltransferase panel: Panel of 15 additional human lysine/arginine methyltransferases; limited to enzymes tested. — Biochemical enzyme inhibition methods; Results first subsection; Figure 1C,D and caption

H3K79me2 chromatin profiling in primary dermal lymphatic endothelial cells

Cell-based study · Primary mouse dermal lymphatic endothelial cells from C57BL/6 embryos; within passage 5 [2]

EPZ5676 reduced H3K79me2 enrichment in promoter/gene-body clusters and representative lymphatic-development loci relative to DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
H3K79me2 enrichment around transcription start sites and representative lymphatic lociChIP-seq enrichment Reduced relative to DMSO; no numerical effect size extracted[2]

Literature-Reported Treatment Conditions

Treatment concentration
2 µM
Exposure duration
7 days
Method
H3K79me2 ChIP-seq; input-chromatin control and DMSO-treated comparator
Vehicle
DMSO
Reported limits
Final DMSO percentage and lot/purity not specified in selected treatment paragraph. Three biological replicates pooled per group/library, not three independently sequenced libraries.
Methods and source locations

Compound reported in the paper: EPZ-5676 (pinometostat); Compound label in the paper: EPZ5676

Cultured-cell chromatin endpoint only; genetic animal phenotypes and genetic RNA-seq not attributed to EPZ5676.

H3K79me2-enrichment Results; Figure 6a,d and caption; Cell culture and MACS; ChIP-Seq and analysis

H3K79me2 enrichment around transcription start sites and representative lymphatic loci: H3K79me2 ChIP-seq; three pooled biological replicates per group/library. Mean tag-density profiles and locus tracks include input controls. — H3K79me2-enrichment Results; Figure 6a,d and caption; Cell culture and MACS; ChIP-Seq and analysis

Pinometostat (EPZ-5676) In Vivo Studies

In MV4-11 rat xenografts, continuous intravenous EPZ-5676 at 70 mg/kg/day for 21 days produced complete tumor regressions. At 35 mg/kg/day continuously, or 67 mg/kg/day infused for 8 hours daily, the response was tumor stasis with subsequent regrowth. Efficacy depended on exposure schedule in this model. [1]

In a separate OCI-AML3 DNMT3A-mutant AML rat xenograft study, continuous intravenous EPZ-5676 for 21 days inhibited tumor growth, with statistical significance reported at 70 mg/kg/day. The 35 mg/kg/day cohort did not establish the same significant response; complete regression was not reported for this experiment. [3]

Continuous versus intermittent infusion in MV4-11 rat xenografts

Animal study · Subcutaneous MV4-11 human leukemia xenografts in female athymic nude rats (rnu/rnu) [1]

The first efficacy experiment compared two continuous doses, an intermittent schedule and vehicle. Durable regression at the higher continuous dose contrasted with less durable stasis in other treatment groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume relative to vehicleTumor-growth comparison P ≤ .0005 for each treated group versus vehicle[1]

Conditions shared by the study groups

Route
Intravenous infusion
Treatment course
21 days
Vehicle
5% hydroxypropyl-β-cyclodextrin in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle control
Vehicle only
Vehicle infusion cohortReference tumor-growth cohort; n = 10.[1]
Continuous EPZ-5676, 70 mg/kg/day
70 mg/kg/day
Vehicle infusion cohortComplete tumor regressions; most rats showed little or no regrowth for more than 30 days after treatment ended, through study day 52. n = 10.[1]
Continuous EPZ-5676, 35 mg/kg/day
35 mg/kg/day
Vehicle infusion cohortTumor stasis sustained for about 7 days after treatment stopped. n = 10.[1]
Intermittent EPZ-5676, 67 mg/kg/day
67 mg/kg/day
Vehicle infusion cohortTumor stasis followed by resumed growth several days after the last infusion; less durable response than similar daily dose continuously. n = 10.[1]
Vehicle control
Model: Subcutaneous MV4-11 human leukemia xenografts in female athymic nude rats (rnu/rnu)
Frequency: Continuous infusion
Continuous EPZ-5676, 70 mg/kg/day
Model: Subcutaneous MV4-11 human leukemia xenografts in female athymic nude rats (rnu/rnu)
Frequency: Continuous, 24 hours/day
Continuous EPZ-5676, 35 mg/kg/day
Model: Subcutaneous MV4-11 human leukemia xenografts in female athymic nude rats (rnu/rnu)
Frequency: Continuous, 24 hours/day
Intermittent EPZ-5676, 67 mg/kg/day
Model: Subcutaneous MV4-11 human leukemia xenografts in female athymic nude rats (rnu/rnu)
Frequency: 8 hours/day
Methods and source locations

Compound reported in the paper: EPZ-5676 (pinometostat); Compound label in the paper: EPZ-5676

Preclinical ectopic rat xenograft response, without clinical efficacy inference.

Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Tumor volume relative to vehicle: Median tumor sizes, n = 10 per group; repeated-measures ANOVA with Dunnett posttest. No volume decimals inferred from curves. — Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Vehicle control · Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Continuous EPZ-5676, 70 mg/kg/day · Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Continuous EPZ-5676, 35 mg/kg/day · Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Intermittent EPZ-5676, 67 mg/kg/day · Figure 5A and caption; first efficacy Results; Rat MV4-11 xenograft methods

Tumor-growth inhibition in DNMT3A-mutant OCI-AML3 rat xenografts

Animal study · Subcutaneous OCI-AML3 DNMT3A-mutant AML xenografts in female athymic nude rats (Hsd:RH-Foxn1rnu) [3]

Dose-dependent tumor-growth inhibition reached significance at 70 mg/kg/day. Activity in this second leukemia model does not imply uniform genotype-independent responses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
OCI-AML3 tumor growth relative to vehicleTumor-growth inhibition Significant in the 70 mg/kg/day cohort; Figure 6C labels P < .05[3]

Conditions shared by the study groups

Route
Intravenous infusion
Frequency
Continuous infusion
Treatment course
21 days, followed by 7-day drug holiday
Vehicle
5% hydroxypropyl-β-cyclodextrin in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle control
Vehicle only
Vehicle infusion cohortReference cohort; N = 8 animals.[3]
EPZ-5676, 35 mg/kg/day
35 mg/kg/day
Vehicle infusion cohortLower tumor-growth curve than vehicle; Results identify statistical significance only at 70 mg/kg/day. N = 8 animals.[3]
EPZ-5676, 70 mg/kg/day
70 mg/kg/day
Vehicle infusion cohortSignificant tumor-growth inhibition versus vehicle; no complete-regression claim. N = 8 animals.[3]
Vehicle control
Model: Subcutaneous OCI-AML3 DNMT3A-mutant AML xenografts in female athymic nude rats (Hsd:RH-Foxn1rnu)
EPZ-5676, 35 mg/kg/day
Model: Subcutaneous OCI-AML3 DNMT3A-mutant AML xenografts in female athymic nude rats (Hsd:RH-Foxn1rnu)
EPZ-5676, 70 mg/kg/day
Model: Subcutaneous OCI-AML3 DNMT3A-mutant AML xenografts in female athymic nude rats (Hsd:RH-Foxn1rnu)
Methods and source locations

Compound reported in the paper: EPZ-5676 (pinometostat); Compound label in the paper: EPZ-5676

Rat tumor-growth result only; not a claim about primary human AML samples or an Adooq lot.

Cell culture and reagents; Nude rat xenografts, efficacy cohort; in-vivo efficacy Results; Figure 6C and caption

OCI-AML3 tumor growth relative to vehicle: N = 8 animals/cohort; error bars are SD. General statistics list Student t test and one-way ANOVA without exact test assignment to this panel. — Cell culture and reagents; Nude rat xenografts, efficacy cohort; in-vivo efficacy Results; Figure 6C and caption

Vehicle control · Cell culture and reagents; Nude rat xenografts, efficacy cohort; in-vivo efficacy Results; Figure 6C and caption

EPZ-5676, 35 mg/kg/day · Cell culture and reagents; Nude rat xenografts, efficacy cohort; in-vivo efficacy Results; Figure 6C and caption

EPZ-5676, 70 mg/kg/day · Cell culture and reagents; Nude rat xenografts, efficacy cohort; in-vivo efficacy Results; Figure 6C and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1380288-87-8
Applications

DOT1L Inhibitor

Formula C30H42N8O3
Molecular Weight 562.7
Synonyms EPZ5676
SMILES
CC(C)N(C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)[C@H]1C[C@@H](CCc2nc3ccc(C(C)(C)C)cc3[nH]2)C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 88 mg/mL (156.38 mM)
Water Insoluble
Ethanol Warmed: 81 mg/mL (143.94 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Pinometostat (EPZ-5676) Research References

  1. [1] Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia Blood (2013). PMID: 23801631 DOI: 10.1182/blood-2013-04-497644 Source material
  2. [2] Yoo H, Lee YJ, Park C, et al. Epigenetic priming by Dot1l in lymphatic endothelial progenitors ensures normal lymphatic development and function Cell death & disease (2020). PMID: 31908356 DOI: 10.1038/s41419-019-2201-1 Source material
  3. [3] Rau RE, Rodriguez BA, Luo M, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia Blood (2016). PMID: 27335278 DOI: 10.1182/blood-2015-11-684225 Source material

Publications

2 publications citing this product

  1. Yoo H, .et al. , Cell Death Dis, 2020, Jan; 11(1): 14 PMID: 31908356
  2. Guang Bai, .et al. , Epigenetics of Chronic Pain, 2019, Pages 1-48

Added to your cart

View Cart Checkout
Loading...